BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Vestergaard AS, Skjøth F, Larsen TB, Ehlers LH. The importance of mean time in therapeutic range for complication rates in warfarin therapy of patients with atrial fibrillation: A systematic review and meta-regression analysis.PLoS One. 2017;12:e0188482. [PMID: 29155884 DOI: 10.1371/journal.pone.0188482] [Cited by in Crossref: 29] [Cited by in F6Publishing: 21] [Article Influence: 5.8] [Reference Citation Analysis]
Number Citing Articles
1 Emren ZY, Şenöz O, Erseçgin A, Emren SV. Evaluation of Bleeding Rate and Time in Therapeutic Range in Patients Using Warfarin Before and During the COVID-19 Pandemic-Warfarin Treatment in COVID-19. Clin Appl Thromb Hemost 2021;27:10760296211021495. [PMID: 34142564 DOI: 10.1177/10760296211021495] [Reference Citation Analysis]
2 Proietti M, Marzona I, Vannini T, Tettamanti M, Fortino I, Merlino L, Basili S, Mannucci PM, Boriani G, Lip GYH, Roncaglioni MC, Nobili A. Long-Term Relationship Between Atrial Fibrillation, Multimorbidity and Oral Anticoagulant Drug Use. Mayo Clin Proc 2019;94:2427-36. [PMID: 31668449 DOI: 10.1016/j.mayocp.2019.06.012] [Cited by in Crossref: 29] [Cited by in F6Publishing: 20] [Article Influence: 9.7] [Reference Citation Analysis]
3 Falamić S, Lucijanić M, Ortner-hadžiabdić M, Marušić S, Bačić-vrca V. Pharmacists’ influence on adverse reactions to warfarin: a randomised controlled trial in elderly rural patients. Int J Clin Pharm 2019;41:1166-73. [DOI: 10.1007/s11096-019-00894-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
4 Fawzy AM, Lip GYH. Anticoagulation in elderly patients with nonvalvular atrial fibrillation: A balancing act. Heart Rhythm 2019;16:38-40. [PMID: 30240797 DOI: 10.1016/j.hrthm.2018.09.011] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
5 Urbonas G, Valius L, Šakalytė G, Petniūnas K, Petniūnienė I. The Quality of Anticoagulation Therapy among Warfarin-Treated Patients with Atrial Fibrillation in a Primary Health Care Setting.Medicina (Kaunas). 2019;55. [PMID: 30650565 DOI: 10.3390/medicina55010015] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
6 Zaman JAB, Bhandari AK. Oral Anticoagulants in Patients With Atrial Fibrillation and End-Stage Renal Disease. J Cardiovasc Pharmacol Ther 2019;24:499-508. [PMID: 31284744 DOI: 10.1177/1074248419858116] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
7 Mckenzie JA, Wilson-Clarke C, Prout J, Campbell J, Douglas RD, Gossell-Williams M. Improving warfarin therapy through implementation of a hospital-based pharmacist managed clinic in Jamaica. Pharm Pract (Granada) 2018;16:1214. [PMID: 30637024 DOI: 10.18549/PharmPract.2018.04.1214] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
8 Paquette M, Witt DM, Holbrook A, Skov J, Ansell J, Schünemann HJ, Wiercioch W, Nieuwlaat R. A systematic review and meta-analysis of supplemental education in patients treated with oral anticoagulation. Blood Adv 2019;3:1638-46. [PMID: 31138592 DOI: 10.1182/bloodadvances.2019000067] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
9 Tavares LC, Marcatto LR, Santos PCJL. Genotype-guided warfarin therapy: current status. Pharmacogenomics 2018;19:667-85. [PMID: 29701078 DOI: 10.2217/pgs-2017-0207] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 5.5] [Reference Citation Analysis]
10 Mertens BJ, Kwint HF, Belitser SV, van der Meer FJM, van Marum RJ, Bouvy ML. Effect of multidose drug dispensing on the time in therapeutic range in patients using vitamin-K antagonists: A randomized controlled trial. J Thromb Haemost 2020;18:70-8. [PMID: 31469508 DOI: 10.1111/jth.14625] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
11 Mitsuntisuk P, Nathisuwan S, Junpanichjaroen A, Wongcharoen W, Phrommintikul A, Wattanaruengchai P, Rattanavipanon W, Chulavatnatol S, Chaiyakunapruk N, Likittanasombat K, Lip GYH. Real-World Comparative Effectiveness and Safety of Non-Vitamin K Antagonist Oral Anticoagulants vs. Warfarin in a Developing Country. Clin Pharmacol Ther 2021;109:1282-92. [PMID: 33113153 DOI: 10.1002/cpt.2090] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
12 Neumann I, Izcovich A, Aguilar R, Basantes GL, Casais P, Colorio CC, Esposito MCG, Lázaro PPG, Meillon-García LA, Pereira J, Rezende SM, Serrano JC, Valle MLT, Vera F, Karzulovic L, Rada G, Schünemann H. ASH, ABHH, ACHO, Grupo CAHT, Grupo  CLAHT, SAH, SBHH, SHU, SOCHIHEM, SOMETH, Sociedad Panameña de Hematología, SPH, and SVH 2021 guidelines for management of venous thromboembolism in Latin America. Blood Adv 2021;5:3032-46. [PMID: 34374748 DOI: 10.1182/bloodadvances.2021004267] [Reference Citation Analysis]
13 Fawzy AM, Yang WY, Lip GY. Safety of direct oral anticoagulants in real-world clinical practice: translating the trials to everyday clinical management. Expert Opin Drug Saf 2019;18:187-209. [PMID: 30712419 DOI: 10.1080/14740338.2019.1578344] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
14 Priksri W, Rattanavipanon W, Saejear W, Tanyasaensook K, Phrommintikul A, Chulavatnatol S, Nathisuwan S. Incidence, risk factors, and outcomes of warfarin-associated major bleeding in Thai population. Pharmacoepidemiol Drug Saf 2019;28:942-50. [DOI: 10.1002/pds.4781] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
15 Martín-Sánchez RÁ, Lorenzo-Villalba N, Calvo-Elías AE, Dubón-Peralta EE, Chocrón-Benbunan CE, Cano-de Luque CM, López-García L, Rivas-Molinero M, Outón-González C, Marco-Martínez J, Calvo-Manuel E, Andres E, Méndez-Bailón M. Clinical Impact of the Time in Therapeutic Range on Early Hospital Readmission in Patients with Acute Heart Failure Treated with Oral Anticoagulation in Internal Medicine. Medicina (Kaunas) 2021;57:365. [PMID: 33918627 DOI: 10.3390/medicina57040365] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
16 Perreault S, Shahabi P, Côté R, Dumas S, Rouleau-Mailloux É, Feroz Zada Y, Provost S, Mongrain I, Dorais M, Huynh T, Kouz S, Diaz A, Blostein M, de Denus S, Turgeon J, Ginsberg J, Lelorier J, Lalonde L, Busque L, Kassis J, Talajic M, Tardif JC, Dubé MP. Rationale, design, and preliminary results of the Quebec Warfarin Cohort Study. Clin Cardiol 2018;41:576-85. [PMID: 29542828 DOI: 10.1002/clc.22948] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
17 Bertram V, Yeo K, Anoopkumar‐dukie S, Bernaitis N. Proton pump inhibitors co‐prescribed with warfarin reduce warfarin control as measured by time in therapeutic range. Int J Clin Pract 2019;73. [DOI: 10.1111/ijcp.13382] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
18 Boyce ML, Zayac A, Davis A, Badrick T, Anoopkumar-dukie S, Bernaitis N. Impact of Aspirin on Warfarin Control as Measured by Time in Therapeutic Range. Basic Clin Pharmacol Toxicol 2018;123:504-8. [DOI: 10.1111/bcpt.13037] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
19 Fontil V, Kazi D, Cherian R, Lee SY, Sarkar U. Evaluation of a Health Information Technology-Enabled Panel Management Platform to Improve Anticoagulation Control in a Low-Income Patient Population: Protocol for a Quasi-Experimental Design. JMIR Res Protoc 2020;9:e13835. [PMID: 31929105 DOI: 10.2196/13835] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
20 Chopard R, Piazza G, Hurwitz S, Fanikos J, Goldhaber SZ. Fatal warfarin-associated intracranial hemorrhage in atrial fibrillation inpatients. J Thromb Thrombolysis 2019;47:331-5. [DOI: 10.1007/s11239-018-1767-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
21 Galli F, Borghi L, Faioni E, Cavicchioli M, Ferrari Losi J, Vegni E. Failure of the Anticoagulant Therapy and Psychological Distress: Still Far From a Bridge. Front Psychol 2018;9:1709. [PMID: 30271365 DOI: 10.3389/fpsyg.2018.01709] [Reference Citation Analysis]
22 Noviyani R, Youngkong S, Nathisuwan S, Bagepally BS, Chaikledkaew U, Chaiyakunapruk N, McKay G, Sritara P, Attia J, Thakkinstian A. Economic evaluation of direct oral anticoagulants (DOACs) versus vitamin K antagonists (VKAs) for stroke prevention in patients with atrial fibrillation: a systematic review and meta-analysis. BMJ Evid Based Med 2021:bmjebm-2020-111634. [PMID: 34635480 DOI: 10.1136/bmjebm-2020-111634] [Reference Citation Analysis]
23 Lee SL, Ong TJ, Mazlan-Kepli W, Mageswaran A, Tan KH, Abd-Malek AM, Cronshaw R. Patients’ time in therapeutic range on warfarin among atrial fibrillation patients in Warfarin Medication Therapy Adherence Clinic. World J Cardiol 2021; 13(9): 483-492 [PMID: 34621493 DOI: 10.4330/wjc.v13.i9.483] [Reference Citation Analysis]
24 Székely O, Miyazawa K, Lip GYH. Current and emerging pharmacotherapy for ischemic stroke prevention in patients with atrial fibrillation. Expert Opin Pharmacother 2018;19:1999-2009. [PMID: 30359142 DOI: 10.1080/14656566.2018.1537368] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]